Sangamo Therapeutics, Inc.
7000 Marina Blvd
Brisbane
CA
94005
United States
Tel: (510) 970-6000
Website: https://www.sangamo.com/
Email: hr@sangamo.com
About Sangamo Therapeutics, Inc.
Sangamo Therapeutics is a genomic medicine company building value with cutting-edge work across four distinct but complementary technology platforms – gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. At Sangamo, we are passionate in developing genomic medicines to transform the lives of patients with serious diseases. We transform lives by building a robust, sustainable, differentiated, innovative, and high value genomic medicine pipeline that addresses patients with life-limiting conditions. Sangamo takes pride in being the first to edit endogenous human genes, first to treat patients with gene edited T cells, and first to treat patients with in vivo genome editing. Our top priority is to meet the needs of patients with commitment and compassion. Along with our commitment to science and to our patients, we also endeavor to create an inclusive environment that promotes and values diversity. Sangamo is a company where individuals can flourish, grow and develop their expertise.
We are seeking top talent to join our mission. Let’s build a better future together.
Stock Symbol: SGMO
609 articles with Sangamo Therapeutics, Inc.
-
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results
11/3/2022
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results.
-
Sangamo Therapeutics Announces Third Quarter 2022 Conference Call and Webcast
10/27/2022
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to release its third quarter 2022 financial results after the market closes on Thursday, November 3, 2022.
-
Bay Area Biotech Companies Hiring Now
10/19/2022
The Biotech Bay region is home to 3,418 life sciences companies and 96,574 employees making an average of $148,285. Here's a look at a few of the bay area biotech companies hiring now. -
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Nine Patients
10/12/2022
Sangamo Therapeutics, Inc., a genomic medicine company, announced updated preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease.
-
It's been a busy week for research on rare diseases, with several clinical trials from AnaptysBio, Regenxbio, Sangamo and more posting results from ongoing activities.
-
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated α-gal A Enzyme Activity in Five Longest Treated Patients
8/30/2022
Sangamo Therapeutics, Inc., a genomic medicine company, announced updated preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease.
-
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results
8/4/2022
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2022 financial results.
-
Sangamo Therapeutics Announces Second Quarter 2022 Conference Call and Webcast
7/28/2022
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its second quarter 2022 financial results after the market closes on Thursday, August 4, 2022.
-
European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation
7/21/2022
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Commission (EC) has granted Orphan Medicinal Product Designation (OMPD) to TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product candidate for treatment in solid organ transplantation.
-
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences - June 01, 2022
6/1/2022
Sangamo Therapeutics, Inc., a genomic medicine company, announced that management will be participating in the following investor conferences:
-
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
5/5/2022
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and first quarter 2022 financial results.
-
Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
5/2/2022
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted eight Sangamo abstracts for presentation at the 25th ASGCT Annual Meeting being held May 16-19, 2022, in-person in Washington, D.C. and in a virtual format.
-
Sangamo Therapeutics Announces First Quarter 2022 Conference Call and Webcast
4/28/2022
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2022 financial results after the market closes on Thursday May 5, 2022.
-
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences - Apr 21, 2022
4/21/2022
Sangamo Therapeutics, Inc., a genomic medicine company, announced that management will be participating in the following investor conferences: Bank of America Securities Conference Date.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation
3/29/2022
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced dosing of the first patient in the Phase 1/2 STEADFAST clinical study evaluating TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living donor.
-
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences - Feb 28, 2022
2/28/2022
Sangamo Therapeutics, Inc., a genomic medicine company, announced that management will be participating in the following investor conferences.
-
Sangamo Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
2/24/2022
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported fourth quarter and full year 2021 financial results and recent business highlights.
-
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast
2/17/2022
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and full year 2021 financial results after the market closes on Thursday, February 24, 2022.
-
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease
2/7/2022
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease.